ClinicalTrials.gg
Not yet recruitingNCT07514117EABP-SEMGUpdated Sep 2, 2026

Electroacupuncture With Two Pulse Patterns for Bell's Palsy Using Surface Electromyography Evaluation

An interventional study of sham EA and Electroacupunture(continuous pulse pattern) in Bell Palsy, sponsored by The First Affiliated Hospital of Zhejiang Chinese Medical University. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by The First Affiliated Hospital of Zhejiang Chinese Medical University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This clinical trial is designed to evaluate the therapeutic effects of two EA parameter settings for Bell's palsy and to investigate the electromyographic characteristics of the disease. The main questions it aims to answer are:

  • Can continuous pulse pattern and intermittent pulse pattern of EA improve the symptoms of Bell's palsy?
  • Do continuous pulse pattern and intermittent pulse pattern of EA impact the electromyographic characteristics of facial muscles in patients with Bell's palsy? The researchers will evaluate the effects of continuous pulse pattern and intermittent pulse pattern in treating Bell's palsy by using surface electromyography as an objective indicator of assessment. The trial lasts for 4 weeks and the treatment period lasts for 4 weeks.

Participants will:

  • receive sham EA, EA with a continuous pulse pattern or EA with an intermittent pulse pattern for 3 times weekly for 4 weeks (12 sessions in total).
  • receive assessment of symptom severity and social functioning on Day 0, end of week 2, end of week 4 and 6 months after the disease onset.
02

Conditions studied

  • Bell Palsy

Browse trials for

Keywords

  • Bell's palsy
  • surface electromyography
  • randomized controlled trial
  • electroacupuncture
03

In context

Bell Palsy

85 studies on the registry are indexed under Bell Palsy; 30 are open to participants now.

This study's planned enrollment of 111 is above the median of 42 across 70 interventional studies indexed under Bell Palsy.

Browse Bell Palsy studies →

Lead sponsor

The First Affiliated Hospital of Zhejiang Chinese Medical University is the lead sponsor of 40 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosed clinically as BP, with imaging evidence (brain CT and/or MRI) excluding central nervous system lesions associated with facial palsy
  • the disease duration of 21 days to 3 months, inclusive
  • age 18-70 years
  • voluntary participation and provision of written
  • receipt of prednisolone during the acute phase at a daily dose of 30-60 mg for at least 5 days

Exclusion criteria

Exclusion Criteria:

  • facial paralysis caused by diseases other than Bell's palsy
  • previous facial paralysis
  • present with facial muscle spasm, synkinesis or contracture
  • Ramsay Hunt syndrome
  • history of facial surgery
  • implanted cardiac pacemakers
  • pregnancy or lactation
  • along with other severe uncontrolled diseases, recognition disorder, aphasia or mental disorders
  • present with bilateral facial paralysis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
111 participants (estimated)

Study arms

  • Sham comparator
    sham EA

    Procedure: sham EA

  • Experimental
    electroacupunture with a continuous pulse pattern

    Procedure: Electroacupunture(continuous pulse pattern)

  • Experimental
    Electroacupuncture with a intermittent pulse pattern

    Procedure: Electroacupuncture(intermittent pulse pattern)

Interventions

  • Proceduresham EA

    Non-acupoint locations approximately 5 mm away from the corresponding acupoints used in the continuous pulse pattern and intermittent pulse pattern groups will be selected. Superficial needling will be performed at these non-acupoints to a depth of 1-2 mm, without manual manipulation or intentional elicitation of the de qi sensation. EA devices will be connected to 4 paired points via specially customized wires lacking internal conductors: (1) non-acupoints near 1 cun medial to GB14 and 1 cun lateral to GB14, (2) non-acupoints near BL2 and GB1, (3) non-acupoints near ST4 and SI18, and (4) non-acupoints near Jiachengjiang and ST5. Needles will be retained for 30 min per session. Treatment will be administered three times per week for 4 weeks, for a total of 12 sessions.

  • ProcedureElectroacupunture(continuous pulse pattern)

    Acupoint selection for the continuous pulse pattern group will be guided by the principle of combining both local and distal acupoints, with a depth of 5 to 30mm and de qi sensation: Cuanzhu (BL2), Sizhukong (SJ23), Yuyao(EX-HN4), QiYangbai (three points including GB14, 1 cun medial to GB14, and 1 cun lateral to GB14), Tongziliao (GB1), Quanliao (Sl18), Dicang (ST4), Daying (ST5), Jiache (ST6), Jiachengjiang, Yifeng (SJ17), Sibai (ST2), Yingxiang (Ll20), Taiyang(EX-HN5) on the affected side, and Hegu (L114) bilaterally. EA devices (Hwato SDZ-ⅡB, Suzhou Medical Supplies Co., Ltd.) will be connected to 4 paired points: (1) 1 cun medial to GB14 and 1 cun lateral to GB14, (2) BL2 and GB1, (3)ST4 and SI18, (4) Jiachengjiang and ST5. A continuous pulse pattern at 2 Hz will be used for electrical stimulation with intensity adjusted to the maximum tolerable level below the pain threshold. The EA treatment will last for 30 min per session, three times per week for 4 weeks, 12 sessions in total.

  • ProcedureElectroacupuncture(intermittent pulse pattern)

    Acupoint selection for the intermittent pulse pattern group will be guided by the principle of combining both local and distal acupoints: Cuanzhu (BL2), Sizhukong (SJ23), Yuyao(EX-HN4), QiYangbai (three points including GB14, 1 cun medial to GB14, and 1 cun lateral to GB14), Tongziliao (GB1), Quanliao (Sl18), Dicang (ST4), Daying (ST5), Jiache (ST6), Jiachengjiang, Yifeng (SJ17), Sibai (ST2), Yingxiang (Ll20), Taiyang(EX-HN5) on the affected side, and Hegu (L114) bilaterally. EA devices will be connected to 4 paired points: (1) 1 cun medial to GB14 and 1 cun lateral to GB14, (2) BL2 and GB1, (3)ST4 and SI18, and (4) Jiachengjiang and ST5. An intermittent pulse pattern at 35 Hz will be used for electrical stimulation, with intensity adjusted to the maximum tolerable level below the pain threshold. The EA treatment will last for 30 min per session, three times per week for 4 weeks, 12 sessions in total.

06

What researchers measure

Primary outcomes

  1. Facial Nerve Grading System 2.0(FNGS 2.0)

    FNGS 2.0 is a clinician-rated scale widely used to evaluate the severity of facial nerve dysfunction based on resting symmetry, voluntary facial movements, and synkinesis, with a composite score ranging from 4 to 24. The total score is categorized into Grade I (normal function) to Grade VI (complete paralysis), with higher scores and grades indicating worse facial nerve dysfunction.

    Time frame: Day 0, end of week 2, end of week 4, 6 months after the disease onset.

Secondary outcomes

  1. Root Mean Square ratio(RMS%)

    RMS is an assessment parameter of surface electromyography, and it reflects the amplitude of muscle electrical activity during facial movements. RMS% is the comparison of RMS values between affected side and healthy side, and it can help quantify the degree of recovery and objectively assess the facial muscle activation.

    Time frame: Day 0, end of week 2, end of week 4, 6 months after the disease onset.

  2. Median Frequency ratio (MDF%)

    MDF is one of the sEMG parameters which has potential value in revealing muscle characteristics, such as fatigue patterns. MDF% is the comparison of MDF values between affected side and healthy side.

    Time frame: Day 0, end of week 2, end of week 4, 6 months after the disease onset.

  3. Sunnybrook Grading Scale(SBGS)

    The SBGS is a standardized clinician-rated scale used to assess the severity of facial muscle dysfunction. The score ranges from 0 to 100, with higher score indicating better facial nerve function. An increase in score over time reflects clinical improvement.

    Time frame: Day 0, end of week 2, end of week 4, 6 months after the disease onset.

  4. Facial Disability Index (FDI)

    The FDI includes physical and social subscales. FDI is a patient-reported measure that assesses the physical and social impact of facial dysfunction. The score of each subscale ranges from 0 to 100, with higher scores indicating better function and less disability.

    Time frame: Day 0, end of week 2, end of week 4, 6 months after the disease onset.

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Funk PF, Schneider R, Schramm M, Volk GF, Anders C, Guntinas-Lichius O. Bilateral muscle activation in postparalytic facial synkinesis: a cross-sectional high-resolution surface electromyography study. Sci Rep. 2026 Jan 14;16(1):2057. doi: 10.1038/s41598-026-36015-1. PubMed 41535392 ↗
  • Schneider R, Schramm M, Funk PF, Volk GF, Anders C, Guntinas-Lichius O. Synchronous surface electromyography as objective method to evaluate the outcome of a biofeedback training in patients with facial synkinesis. Sci Rep. 2025 May 19;15(1):17335. doi: 10.1038/s41598-025-01278-7. PubMed 40389431 ↗
  • Balbinot G, Joner Wiest M, Li G, Pakosh M, Cesar Furlan J, Kalsi-Ryan S, Zariffa J. The use of surface EMG in neurorehabilitation following traumatic spinal cord injury: A scoping review. Clin Neurophysiol. 2022 Jun;138:61-73. doi: 10.1016/j.clinph.2022.02.028. Epub 2022 Mar 19. PubMed 35364465 ↗
  • Li J, Kang X, Li K, Xu Y, Wang Z, Zhang X, Guo Q, Ji R, Hou Y. Clinical significance of dynamical network indices of surface electromyography for reticular neuromuscular control assessment. J Neuroeng Rehabil. 2023 Dec 20;20(1):170. doi: 10.1186/s12984-023-01297-3. PubMed 38124144 ↗
  • Guntinas-Lichius O, Volk GF, Olsen KD, Makitie AA, Silver CE, Zafereo ME, Rinaldo A, Randolph GW, Simo R, Shaha AR, Vander Poorten V, Ferlito A. Facial nerve electrodiagnostics for patients with facial palsy: a clinical practice guideline. Eur Arch Otorhinolaryngol. 2020 Jul;277(7):1855-1874. doi: 10.1007/s00405-020-05949-1. Epub 2020 Apr 8. PubMed 32270328 ↗
  • Balbinot G, Li G, Wiest MJ, Pakosh M, Furlan JC, Kalsi-Ryan S, Zariffa J. Properties of the surface electromyogram following traumatic spinal cord injury: a scoping review. J Neuroeng Rehabil. 2021 Jun 29;18(1):105. doi: 10.1186/s12984-021-00888-2. PubMed 34187509 ↗
  • Pozzi M, Rezoagli E, Bronco A, Rabboni F, Grasselli G, Foti G, Bellani G. Accessory and Expiratory Muscles Activation During Spontaneous Breathing Trial: A Physiological Study by Surface Electromyography. Front Med (Lausanne). 2022 Mar 10;9:814219. doi: 10.3389/fmed.2022.814219. eCollection 2022. PubMed 35372418 ↗
  • Felici F, Del Vecchio A. Surface Electromyography: What Limits Its Use in Exercise and Sport Physiology? Front Neurol. 2020 Nov 6;11:578504. doi: 10.3389/fneur.2020.578504. eCollection 2020. PubMed 33240204 ↗
  • Cassoni A, Catalano C, Di Giorgio D, Raponi I, Di Brino M, Perotti S, Valentini V. Masseter-facial neurorrhaphy for facial palsy reanimation: What happens after masseter denervation? Histomorphometric and stomatognathic functional analysis. J Craniomaxillofac Surg. 2020 Jul;48(7):680-684. doi: 10.1016/j.jcms.2020.04.009. Epub 2020 Jun 2. PubMed 32507669 ↗
  • Aoyagi M, Saito O, Tojima H, Maeyama H, Koike Y. Distribution of facial nerve conduction velocities in patients with Bell's palsy. Eur Arch Otorhinolaryngol. 1994 Dec:S514-6. doi: 10.1007/978-3-642-85090-5_205. No abstract available. PubMed 10774437 ↗
  • Eviston TJ, Croxson GR, Kennedy PG, Hadlock T, Krishnan AV. Bell's palsy: aetiology, clinical features and multidisciplinary care. J Neurol Neurosurg Psychiatry. 2015 Dec;86(12):1356-61. doi: 10.1136/jnnp-2014-309563. Epub 2015 Apr 9. PubMed 25857657 ↗
  • Sun J, Liu G, Sun Y, Lin K, Zhou Z, Cai J. Application of Surface Electromyography in Exercise Fatigue: A Review. Front Syst Neurosci. 2022 Aug 11;16:893275. doi: 10.3389/fnsys.2022.893275. eCollection 2022. PubMed 36032326 ↗
  • Karthick PA, Ghosh DM, Ramakrishnan S. Surface electromyography based muscle fatigue detection using high-resolution time-frequency methods and machine learning algorithms. Comput Methods Programs Biomed. 2018 Feb;154:45-56. doi: 10.1016/j.cmpb.2017.10.024. Epub 2017 Nov 9. PubMed 29249346 ↗
  • Khan AJ, Szczepura A, Palmer S, Bark C, Neville C, Thomson D, Martin H, Nduka C. Physical therapy for facial nerve paralysis (Bell's palsy): An updated and extended systematic review of the evidence for facial exercise therapy. Clin Rehabil. 2022 Nov;36(11):1424-1449. doi: 10.1177/02692155221110727. Epub 2022 Jul 5. PubMed 35787015 ↗
  • Baugh RF, Basura GJ, Ishii LE, Schwartz SR, Drumheller CM, Burkholder R, Deckard NA, Dawson C, Driscoll C, Gillespie MB, Gurgel RK, Halperin J, Khalid AN, Kumar KA, Micco A, Munsell D, Rosenbaum S, Vaughan W. Clinical practice guideline: Bell's palsy. Otolaryngol Head Neck Surg. 2013 Nov;149(3 Suppl):S1-27. doi: 10.1177/0194599813505967. PubMed 24189771 ↗
  • Heckmann JG, Urban PP, Pitz S, Guntinas-Lichius O, Gagyor I. The Diagnosis and Treatment of Idiopathic Facial Paresis (Bell's Palsy). Dtsch Arztebl Int. 2019 Oct 11;116(41):692-702. doi: 10.3238/arztebl.2019.0692. PubMed 31709978 ↗
  • Dalrymple SN, Row JH, Gazewood J. Bell Palsy: Rapid Evidence Review. Am Fam Physician. 2023 Apr;107(4):415-420. PubMed 37054419 ↗
  • Tiemstra JD, Khatkhate N. Bell's palsy: diagnosis and management. Am Fam Physician. 2007 Oct 1;76(7):997-1002. PubMed 17956069 ↗
  • Gronseth GS, Paduga R; American Academy of Neurology. Evidence-based guideline update: steroids and antivirals for Bell palsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2012 Nov 27;79(22):2209-13. doi: 10.1212/WNL.0b013e318275978c. Epub 2012 Nov 7. PubMed 23136264 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) collected in this study will not be made available to other researchers.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Oct 2027, 13 months later.

Of 38 non-industry interventional studies with no phase under Bell Palsy, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 25. This study's planned 13 months is above that.

Counting every sponsor, half of 40 studies reached it within 10 months; a quarter within 3 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2026
First posted
Apr 7, 2026
StartEst.
Sep 2026
Primary completionEst.
Oct 2027
CompletionEst.
Dec 2027
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07514117
Lead sponsor
The First Affiliated Hospital of Zhejiang Chinese Medical University
Collaborators
The Third Affiliated hospital of Zhejiang Chinese Medical University
Responsible party
Ruohan Sun (Physician, Department of Acupuncture, The First Affiliated Hospital of Zhejiang Chinese Medical University) — Principal investigator
First posted
Apr 7, 2026
Start date
Sep 2026 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 2, 2026

Study contacts

Ruohan Sun
Contact
srh1207@163.com
86-15757194080
Lexuan Li
Contact
lilexuan00@163.com
86-13588838759

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion